Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in trading and manufacturing of Pharmaceutical drugs and provides services and key solutions in Information Technology.
- Market Cap ₹ 15.2 Cr.
- Current Price ₹ 15.1
- High / Low ₹ 25.8 / 14.4
- Stock P/E 18.4
- Book Value ₹ 21.3
- Dividend Yield 0.00 %
- ROCE -3.09 %
- ROE -6.75 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.71 times its book value
- Company's working capital requirements have reduced from 63.9 days to 36.5 days
Cons
- Promoter holding is low: 16.4%
- Earnings include an other income of Rs.0.55 Cr.
- Promoter holding has decreased over last 3 years: -29.5%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 32.19 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 30.87 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | 1.32 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | 4.10% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | 0.55 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.21 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.46 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | 1.20 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | 0.83 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | -14% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -9% |
| 3 Years: | -27% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 21% |
| Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 11.43 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.16 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 8.88 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 30.57 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 5.10 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 5.49 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 25.23 | 25.47 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 30.57 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 |
| Inventory Days | 91.25 | 19.70 | 0.00 | ||||
| Days Payable | 511.00 | 192.66 | |||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 |
| Working Capital Days | 797.99 | 108.68 | 146.97 | 4.99 | 85.83 | 69.28 | 36.52 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter 30.09.2024 Under Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015.
14 Nov - Board approved unaudited financial results for Q2 2024.
- Unaudited Financial (Standalone And Consolidated) Results For The Quarter And Half Year Ended 30.09.2024 14 Nov
-
Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2024.
8 Nov - Board meeting on November 14 to discuss financial results.
-
Compliance As Per Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 For The Quarter Ended September 30, 2024.
17 Oct - Compliance with SEBI regulations for dematerialization.
-
Closure of Trading Window
30 Sep - Closure of trading window until financial results announcement.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1][2]
a) Pharmaceuticals: Manufacturing & Marketing of Branded Formulations and Custom Manufacturing for companies. Company also caters to various formulators, manufacturers and Research and Development agencies for their Bulk needs and sources and supplies various drugs and allied products & services to companies upon request.
b) Information Technology: Company has taken over Decipher Software Solutions LLC in USA which is an Information Technology services firm, specializing in ERP Implementation, Mobile & Cloud solutions, Product Development, Offshore Services, Technology Integration and Systems Consulting, Software Development Consulting and Management of IT projects.